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Abstract
Background. Remodelling of matrix and tubular basement
membranes (TBM) is a characteristic of polycystic kid-
ney disease. We hypothesized that matrix and TBM degra-
dation by metalloproteinases (MMPs) could promote cyst
formation. We therefore investigated the renal expression
of MMPs in the Han:SPRD rat model of autosomal domi-
nant polycystic kidney disease (ADPKD) and examined the
effect of sirolimus treatment on MMPs.
Methods. 5-week-old male heterozygous (Cy/+) and
wild-type normal (+/+) rats were treated with sirolimus
(2 mg/kg/day) through drinking water for 3 months.
Results. The mRNA and protein levels of MMP-2 and
MMP-14 were markedly increased in the kidneys of
heterozygous Cy/+ animals compared to wild-type +/+
as shown by RT-PCR and Western blot analyses for
MMP-2 and MMP-14, and by zymography for MMP-2.
Strong MMP-2 expression was detected by immunoperoxi-
dase staining in cystic epithelial cells that also displayed
an altered, thickened TBM. Tissue inhibitor of
metalloproteinases-2 (TIMP-2) expressionwas not changed
in Cy/+ kidneys. Sirolimus treatment leads to decreased
protein expression of MMP-2 and MMP-14 in Cy/+,
whereas MMP-2 and MMP-14 mRNA levels and TIMP-2
protein levels were not affected by sirolimus.
Conclusion. In summary, in kidneys of the Han:SPRD rat
model of ADPKD, there is a marked upregulation of MMP-
2 and MMP-14. Sirolimus treatment was associated with a
marked improvement of MMP-2 and MMP-14 overexpres-
sion, and this correlated also with less matrix and TBM
alterations and milder cystic disease.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
is a chronic progressive kidney disease, which is charac-
terized by cystic enlargement of both kidneys. Affected
individuals usually present in the third to fourth decade
of life hypertension, haematuria, polyuria, flank pain, and
progress to end-stage renal disease within 5–10 years after
the development of renal insufficiency [1]. The presence of
numerous fluid-filled cysts is the predominant pathological
feature of PKD. In addition to cyst formation, reorganisa-
tion of tubular basement membranes (TBM) and the devel-
opment of fibrosis within the renal interstitium are char-
acteristics of PKD, suggesting that the extracellular matrix
(ECM) is intensely remodelled [2]. Tubular epithelial cells
play an important role in the synthesis and degradation of
ECM components, which in turn play a regulatory role in
epithelial cell differentiation and growth [3,4].
Matrix metalloproteinases (MMPs) are a large family of
secreted and membrane-bound zinc-dependent endopepti-
dases, which can degrade a wide spectrum of matrix sub-
strates, and therefore represent key enzymes in the turnover
of the extracellular matrix [5–7]. Most MMPs are released
as zymogens before being activated in the extracellular
environment. However, MMP-14, a membrane-bound
metalloproteinase, is processed before its insertion into
specific plasma membrane domains. In addition to its
matrix-degrading properties, MMP-14 mediates the acti-
vation of pro-MMP-2 together with the tissue inhibitor of
metalloproteinases TIMP-2, which acts as a cofactor. Acti-
vation of pro-MMP-2 from this ternary complex is finally
accomplished by a second, non-TIMP-2-bound MMP-14
molecule [7,8]. Thus, net activation of MMP-2 depends
on local MMP-14 and TIMP-2 levels, following the gen-
eral concept that the interaction of a cell with extracellular
matrix is critically determined by the concentrations of
metalloproteinases and their natural inhibitors.
The purpose of the present investigations was to exam-
ine alterations in the expression of MMPs and TIMPs in
a rodent model of PKD, namely the Han:SPRD rat, and
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to correlate these molecules with changes in matrix and
TBM structure. In a previous work, we and others have
demonstrated that sirolimus treatment of Han:SPRD rats
markedly reduced cyst growth and improved renal his-
tology [9,10]. Here, we investigated the renal expression
of MMP-2, MMP-14 and TIMP-2 in the Han:SPRD rat
model of PKD, and examined the effect of sirolimus on the
expression of these molecules.
Subjects and methods
Animals
The study was conducted in heterozygous (Cy/+) and nor-
mal littermate control (+/+) Han:SPRD rats. Only male
rats were used since the disease progresses faster in male
compared with female rats. A colony of Han:SPRD rats
was established in our animal care facility from breeding
pairs that were obtained from the Rat Resource & Research
Center (Columbia, MO, USA). The regulatory commission
for animal studies, a local government agency, approved
the study protocol. The rats had free access to tap water
and a standard rat diet. Rapamycin (Rapamune R© oral so-
lution) was kindly provided by Wyeth-AHP (Schweiz) AG,
Switzerland.
Reagents
The following antibodies from Calbiochem were used
for western blot analyses: anti-MMP-2 (468–483) (Ab-3)
human (mouse), anti-MMP-14 (Ab-4) human (mouse),
anti-TIMP-2 (Ab-2) mouse mAb (67–4H11) and as sec-
ondary antibody the peroxidase goat anti-mouse IgG.
Anti-MMP-2 (Ab-3) clone A-Gel VC2 from Neomarkers
(Fremont, CA, USA) was used for immunohistochemistry.
Experimental protocol
Male Cy/+ (n = 6) and +/+ (n = 4) rats were weaned
and were then treated at 5 weeks of age (n = 10) with
2 mg/kg/day sirolimus, as described previously [9]. Addi-
tional male Cy/+ (n = 4) and +/+ rats (n = 3) were not
treated and served as controls. The drug was administered
in the form of a Rapamune R© oral solution in the drink-
ing water for 3 months. The concentration of sirolimus
(Rapamune R© oral stock solution 1 mg/ml) was adjusted
according to rat body weight. After 3 months of treatment,
the rats were anesthetized with isoflurane, the kidneys were
removed, decapsulated and snap frozen in liquid nitrogen.
Samples were stored at −80◦C.
RNA extraction
Frozen kidney tissues were homogenized in lysis buffer
(RNeasy; Qiagen), using Lysing Matrix D tubes and a
BIO101 FastPrep R© Instrument (QBiogene, Basel, Switzer-
land). The total RNA isolation (including DNase treatment)
was performed from the homogenates according to theman-
ufacturer’s instructions (RNeasy; Qiagen). All aliquots of
sampleswere stored at−70◦Cuntil use. RNAconcentration
wasmeasured by using a spectrophotometer, and the quality
was analyzed by Bioanalyzer 2100 electropherograms
(Agilent, Waldbronn, Germany).
Genechip expression analysis
Affymetrix GeneChip R© rat genome 230 2.0 arrays
were used according to the manufacturer’s instructions
(Affymetrix Inc, Santa Clara, CA). Briefly, 5 µg of total
RNA from Cy/+ and +/+ rat kidneys was used as starting
material to generate biotin-labeled cRNA samples, which
includes cDNA synthesis using oligo-dT/T7 primers,
followed by in vitro transcription (one-cycle labeling
protocol). Labeled cRNA samples (15 µg) were randomly
fragmented to 35–200 bp and hybridized on arrays for 16 h,
and arrays were washed. The fluorescent intensity emitted
by the labeled target was measured by an Affymetrix
GeneChip Scanner 3000. Finally, the hybridization images
were analyzed using Affymetrix GCOSTM 1.2
software.
Reverse transcription and real-time taqman PCR analyses
for MMP-2, MMP-14 and TIMP-2
RT and Taqman PCR analyses for MMP-2, MMP-14 and
TIMP-2 were performed as described previously [11].
Total RNA was reverse-transcribed and PCR was carried
out using TaqMan Universal PCR Master Mix (Applied
Biosystems; containing AmpliTaq Gold DNA Polymerase),
Gene Expression Assay Mix and cDNA. Real-time PCR
analyses were performed with the ABI PRISM 7500 Se-
quence Detection System (Applied Biosystems, Rotkreuz,
Switzerland), according to the instructions of Applied
Biosystems. The expression levels of the 18S subunit of
ribosomal RNA (18S rRNA) were used as a housekeeping
gene. Relative quantification of all targets was calculated
by the comparative cycle threshold method outlined by the
manufacturer (User Bulletin No. 2; Applied Biosystems).
ForMMP-2,MMP-14, TIMP-2 and 18S, assays-on-demand
gene expression products were used as described in the
manufacturer’s protocol (Applied Biosystems).
Protein extraction
A fresh ice-cold lysis buffer was prepared for protein
extraction from frozen rat kidneys. The lysis buffer con-
sisted of 50 mM Tris base, pH 7.4; 150 mM NaCl; 1%
deoxycholate; 1% SDS; and 1% Triton X-100. Immedi-
ately before use, the lysis buffer was supplemented with 1
mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and
a protease and phosphatase inhibitor cocktail. Each sam-
ple was homogenized using a Dounce homogenizer. All
aliquots of samples were stored at −70◦C until use. Protein
concentrations were determined using the BCATM Protein
Assay reagent kit (Pierce, Lausanne, Switzerland).
Zymography for MMP-2
Activity of the gelatinase MMP-2 was analyzed by gelatin
substrate zymography. Briefly, 20 µg of each sample was
loaded on a 7.5% SDS-PAGE gel containing 0.1% gelatin.
After migration, gels were first incubated for 1 h in a mix-
ture containing 2.5% Triton X-100 and 50 mM Tris/HCl
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pH 8.0, then overnight in 50 mM Tris/HCl pH 8.0, 5 mM
CaCl2, 5 µM ZnCl2. After incubation, gels were stained
with 0.4% Coomassie blue and destained with 10% acetic
acid and 50% methanol. The white bands obtained on the
gels corresponding to MMP-2 activity were analyzed by
densitometry (Scion Image Corporation) after scanning.
The Precision Plus ProteinTM Standard (Biorad, Reinach,
Switzerland) was used as molecular weight marker, and a
recombinant MMP-2 protein from OncogeneTM was used
as positive control.
Western blot analysis for MMP-2, MMP-14 and TIMP-2
Equal amounts of protein samples and a reduced load-
ing buffer were incubated for 5 min at 95◦C. Samples
were loaded on a 7.5% SDS-PAGE gel containing 40%
acrylamid and 10% SDS. After migration, the proteins of
the gels were transferred onto a supported nitrocellulose
membrane (Biorad). The blots were blocked with 5% milk
for 1 h at room temperature and were then incubated
overnight at 4◦C in a blocking buffer containingmonoclonal
rat anti-α tubulin, or monoclonal mouse anti-MMP-2, anti-
MMP-14 or anti-TIMP-2 (dilutions 1:2000, 1:100, 1:25,
1:50). Subsequently, the blots were washed in a PBS-Tween
solution and were incubated with a goat anti-mouse HRP-
conjugated secondary antibody (dilution 1:1000). Finally,
the membranes were incubated for 5 min in an enhanced
chemiluminescent (ECL+) reagent (Amersham Pharmacia
Biotech), followed by the exposure to Hyperfilm (SuperRX
Fujifilm). The molecular weight of the bands of interest
was determined by the Precision Plus ProteinTM Standard
and by recombinant MMP-2 and TIMP-2 proteins from
OncogeneTM as positive controls.
Immunohistochemical detection of MMP-2
Rat kidney slices of about 2 mm thickness were cut
immediately after the excision. The slices were fixed by
immersion for 2 h at 4◦C in 4% freshly de-polymerized
paraformaldehyde in phosphate-buffered saline (PBS), de-
hydrated through an alcohol series and embedded in paraf-
fin. For immunohistochemistry, 3 µm thick sections were
cut and rehydrated through an alcohol series. They were
microwaved for 10 min in a 0.01M sodium citrate buffer,
pH 6.0. After blocking with 5% normal goat serum, the sec-
tions were incubated overnight at 4◦C with the primary an-
tibody. A mouse monoclonal antibody against MMP-2 was
diluted 1:500. After three washes in PBS, the binding sites
of the primary antibody were revealed with the Vectastain
ABC kit (Vector Laboratories, Burlingame, CA, USA) us-
ing 3,3’-diaminobenzidine tetrahydrochloride as substrate,
according to the instructions of the supplier. The sections
were then washed in water and were counterstained with the
periodic acid-Schiff (PAS) reagent. The nuclei were stained
with haematoxylin.
Statistics
All data are expressed as means ± SD and were considered
normally distributed. Data were analyzed by applying a
t-test using the GraphPad Prism software version 4.0 for
windows (San Diego, CA, USA). The analysis of Genechip
MAS5 normalized expression values was performed using
GeneSpring 6.1.1 (Agilent, CA, USA). A t-test was car-
ried out between the group of samples belonging to the
respective conditions, and p-values <0.05 were considered
significant.
Results
Affymetrix gene chip analysis
Microarray analysis revealed an upregulation of several in-
teresting genes in the family of metalloproteinases in Cy/+
kidneys, compared to wild-type+/+ kidneys. In particular,
we found a significant upregulation of MMP-2 (3.9-fold,
P < 0.05) and MMP-14 (3.3-fold P < 0.05) in the mi-
croarrays (Figure 1A). Sirolimus treatment did not block
this upregulation (data not shown). Real-time Taqman PCR
analysis of RNA from Cy/+ and control +/+ rat kidneys
was performed to determine steady-state mRNA changes
for MMP-2, MMP-14 and TIMP-2. Figure 1B shows a sig-
nificant increase of MMP-2 mRNA (2.2-fold, P < 0.05),
of MMP-14 mRNA (2.4-fold, P < 0.05) and an unchanged
TIMP-2 mRNA level in Cy/+ rats compared with +/+
rats, thereby validating the expression data obtained from
microarray experiments.
Enhanced MMP-2 expression and activity in Cy/+ kidneys
is reduced in sirolimus-treated rat kidneys
The expression of MMP-2 protein was then analyzed by
western blot (Figure 2A), and quantified by densitome-
try (Figure 2B). Both the pro-form (72 kD) and the active
formofMMP-2 (66 kD)were detected inwild-type rats, and
these forms were not altered by treatment with sirolimus.
There was a significant increase in the expression levels
of the pro-form and the active form of MMP-2 in un-
treated heterozygous (Cy/+) vs untreated wild-type (+/+)
rats (5.08- and 3.17-fold increase, respectively; P < 0.05).
Treatment with sirolimus effectively decreased the expres-
sion of MMP-2 pro-form and active form by 3.08-fold and
2.57-fold (P < 0.05). In Cy/+ rats, respectively, compared
to untreated Cy/+ rats (Figure 2B).
Analysis of MMP-2 activity with zymography was then
performed to correlate the level of MMP-2 expression
with its activity (Figure 3). A weak activity for the 72 kD
pro-form of MMP-2 was detectable in +/+ rats; however,
a significantly stronger activity was measured in Cy/+ ani-
mals (6.65-fold increase of the pro-form activity, P< 0.01).
Activity for the 66 kD active form could not be detected
in +/+ kidneys but was detectable in Cy/+ rats. Treatment
with sirolimus was associated with a significant decrease in
the pro-MMP-2 activity (1.55-fold decrease; P< 0.01), and
the activity of the 66 kD active formwas again undetectable.
Immunohistochemical staining in Cy/+ kidneys shows
predominant tubular upregulation of MMP-2
In +/+ rats, immunohistochemistry revealed a moderate
to strong expression of MMP-2 in interstitial cells, in the
endothelia of peritubular capillaries and in the epithelium of
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Fig. 1. (A) Microarray results of increased levels of MMP-2 and MMP-14 gene expression in Cy/+ heterozygous rats compared with +/+ wild-type
rats. TIMP-2 mRNA levels were not modified. (B) Real-time TaqMan PCR analysis of MMP-2, MMP-14 and TIMP-2 gene expression in the same set
of rats confirmed the original microarray data. The results are expressed as mean ± SD. ∗P < 0.05 compared to the +/+ group, n = 4 to 6 per group.
the capsule of Bowman (Figure 4A).Most of the convoluted
part of the proximal tubule showed aweak immunolabeling.
MMP-2 was not detected in the late convoluted part, the
straight part of the proximal tubule, the whole distal tubule
and the collecting duct.
In histologically normal tubular profiles in Cy/+ rats,
the expression of MMP-2 was similar to +/+ rats (Figure
4B). In dilated tubules, there was a striking heterogeneity of
immunolabeling (Figure 4C). The expression was similar to
+/+ rats in epithelial cells that lookedmorphologically nor-
mal. In contrast, MMP-2 staining in Cy/+ was moderate to
very strong where the epithelium displayed an abnormally
developed tubular basement membrane, as revealed by
PAS staining (Figure 4D). The association between a high
expression of MMP-2 and a modified basement membrane
was found in the proximal tubule, in the capsule of Bowman
and in the distal tubule. MMP-2 was expressed in all large
cysts, mostly at a high level (Figure 4E).
Cysts in Cy/+ sirolimus-treated rats displayed similar
levels of MMP-2 as cysts of placebo-treated rats. Ex-
pression of MMP-2 was also focally observed in tubules,
which displayed thickening of the basement membrane
(Figure 4F).
Effect of sirolimus treatment on MMP-14 and TIMP-2
expression in Cy/+ kidneys
In addition to its matrix-degrading properties, MMP-14
mediates the activation of pro-MMP-2 together with the tis-
sue inhibitor of metalloproteinases TIMP-2, which acts as a
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Fig. 2. MMP-2 expression. (A)Western blot and (B) densitometry confirmed the upregulation of the pro- and active forms ofMMP-2 in Cy/+ compared
to +/+. Treatment with sirolimus decreased these levels near to those of the wild-type. Two representative samples for each group are depicted. ∗P <
0.05 compared with the untreated or treated wild-type (+/+) rats, #P < 0.05 compared with the untreated heterozygous (Cy/+) rats, n = 4 per group.
cofactor. Since MMP-14 and TIMP-2 play decisive roles in
MMP-2 activation, we hypothesized that levels of MMP-14
and TIMP-2 would correlate with the increase of MMP-2
in the Cy/+ kidneys of ADPKD rats. The expression of
MMP-14 was investigated by western blot analysis. Figure
5 shows that MMP-14 was detected in two different forms,
as reflected by the bands at 63 and 58 kD, corresponding
to the MMP-14 proform and the active form, respectively.
MMP-14 protein expression was stronger in Cy/+ com-
pared to +/+ rat kidneys (Figure 5A). Densitometry (Fig-
ure 5B) revealed a 4.55-fold and 6.35-fold increase in both
forms of MMP-14 in Cy/+ compared to +/+ rat kidneys
(P < 0.05). Sirolimus was again associated with reduced
MMP-14 protein levels (4.93-fold and 5.73-fold, respec-
tively; P < 0.05) down to levels observed in +/+ control
rats.
TIMP-2 is involved in MMP-2 activation in conjunction
with MMP-14, but can also inhibit activation of MMP-2
[12]. Three different forms of TIMP-2 were found by west-
ern blot analysis (Figure 6A). The active form of TIMP-2
at 27 kD and the bimolecular complex of TIMP-2/MMP-14
at 70 kD were not significantly higher in Cy/+ rat kidneys
compared with +/+, and were not affected by treatment
with sirolimus (Figure 6B). However, the dimeric complex
of TIMP-2 at 54 kD increased approximately 1.59-fold
(P < 0.05) when compared with the untreated +/+ rats,
and tended to be reduced (1.45-fold; non significant) in
sirolimus-treated rats. Interestingly, of all three forms, the
TIMP-2/MMP-14 complex was the least expressed; the
TIMP-2 active form had the highest overall expression level
of the three forms.
Discussion
Others and we have shown that treatment with the mTOR
inhibitors sirolimus and everolimus delays the loss of renal
function and retards cyst development in Han-SPRD rats
[9,13–15]. Here, we show that treatment of Han:SPRD rats
with sirolimus was associated with a marked improvement
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Fig. 3. (A) Zymography showed increased activities of pro- and active forms of MMP-2 (72 and 66 kDa respectively) in untreated heterozygous
(Cy/+) rats compared with untreated wild-type (+/+) rats. MMP-2 activities were not modified by sirolimus treatment in +/+, but were decreased
in Cy/+ as determined by (B) densitometry. Ctrl = purified MMP-2 antigen (Calbiochem, Switzerland) as a reference for MMP-2 identification. Two
representative samples for each group are depicted. ∗∗P < 0.01 compared with the untreated or treated wild-type (+/+) rats, #P < 0.05 compared with
the untreated heterozygous (Cy/+) group, n = 4 per group.
ofMMP-2 andMMP-14 overexpression, and this correlated
also with less matrix and TBM alterations and milder cystic
disease.
By gene array analysis, we identifiedMMP-2 andMMP-
14 as the two major MMPs, which are markedly enhanced
in Han-SPRD rat kidneys with PKD. RT-PCR analysis,
and the examination of MMP-2 and MMP-14 protein by
western blot and zymography confirmed the upregulation.
In agreement with our findings, the abnormalities in the ex-
pression of MMPs have been described for human [16,17]
and animal models of PKD [18–20]. In humans, increased
levels of MMP-2 and -9 have been preferentially localized
in tubular epithelia forming renal cysts. In animal models,
it has been demonstrated that cystic kidney tubules can
synthesize and secrete high levels of MMPs, in particular
MMP-2 and MMP-14 [19,21,22]. In contrast to our find-
ings, Schaefer et al. found a decrease of MMP-2 expression
and activity in Cy/+ rats in early stages of PKD. However,
thismay be explained by several factors. In our experiments,
we used whole kidney homogenate instead of isolated
proximal tubules because MMP-2 has been localized to the
interstitium and to the epithelial cells of all cyst-forming
nephron segments [18]. Also, our rats were at a latter stage
of disease progression. The expression of genes involved in
fibrosis and inflammation increase with age in Cy/+ rats
and further explain our finding of increased MMP-2 ex-
pression [20]. MMP-2 expression was prominent in tubular
epithelial cells lining cysts and with an altered basement
membrane. Those two features remained associated at the
different stages of cyst growth, indicating that cystogen-
esis is associated with tubular induction of MMP-2. The
parallel increase of cyst growth and expression of genes
involved in inflammation and fibrosis suggests that MMPs
may regulate collagen accumulation at sites where cystic
transformation occurs, linking the progression of cyst
formation with ECM remodelling in PKD.
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Fig. 4. Immunohistochemistry for MMP-2 in kidney sections. In wild-type (+/+), the segments S1 and S2 of the proximal (P) tubule display a weak
immunoreactivity; the segment S3 and the distal (D) tubule are negative (A). Patches of cells that produce excess amounts of basement membrane
(arrows in B and C) represent the earliest histological alteration in (B) proximal and (C) distal tubules in Cy/+ kidneys. The cells in such patches
up-regulate MMP-2. Note the sharp transition in (D) between the normal and the altered epithelium with its thickened basement membrane and its high
immunoreactivity for MMP-2. (E)MMP-2 remains abundant in the large cysts with their thin epithelia. In Cy/+ sirolimus-treated rats, MMP-2 tubular
expression is detected in cysts and focally in tubules, which displayed thickening of the basement membrane (F).
Remodelling ECM has been hypothesized as a necessary
step for cyst expansion [21]. In a study which also used the
Han:SPRD rat, treatment with the global MMP inhibitor
batimastat reduced cyst number and kidney weight [18].
Treatment of cystic mice withWAR-1 andWTACE2,MMP
inhibitors that share some degree of activity against MMP-
9 and MMP-13 slowed disease progression [23], pointing
again to an important role of MMPs in cyst formation
in PKD. Interestingly, transgenic expression of MMP-2 in
proximal tubular epithelial leads to structural alterations in
the tubular basement membrane, fibrosis and renal failure
[24].
Sirolimus is an immunosuppressant with potent antipro-
liferative effects on non-lymphoid cells.We and others have
previously shown that sirolimus effectively retards renal
cyst development in the Han:SPRD rat [9,10]. Shilling-
ford et al. have confirmed the potent anticystic effects of
sirolimus in additional animal models of PKD [13]. Inhibi-
tion of the mTOR signalling pathway with sirolimus most
likely inhibits cell proliferation in PKD via control of ribo-
somal translation.However, thismay not be the solemode of
action. The reduced MMP-2 and MMP-14 protein expres-
sion, which occurred in response to the sirolimus treatment,
was not associated with reduced mRNA levels. Sirolimus
controls gene expression at the translational level via in-
hibition of downstream protein kinases that are required
for translation of mRNAs [25]. Effectors of the mTOR
pathway are upregulated in the kidneys of Cy/+ rats, and
protein expression of MMP-2 and MMP-14 is transduced
at least in part by these effectors of the mTOR pathway
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Fig. 5. MMP-14 protein expression. (A) Western blot analysis and (B) densitometry showed an increase of pro- and active forms of MMP-14 protein
(63 and 58 kD respectively) in the kidneys of untreated heterozygous (Cy/+) rats compared with untreated wild-type (+/+) rats. Sirolimus treatment
did not affect both MMP-14 forms in +/+ rats. MMP-14 protein levels decreased in kidneys of Cy/+ rats treated with sirolimus. Two representative
samples for each group are depicted. ∗P < 0.05 compared with the untreated wild-type (+/+), #P < 0.05 compared with the untreated heterozygous
(Cy/+) group, n = 4 per group.
in vitro [2,26]. Thus, our results indicate that MMP-2/-14
protein expression in response to sirolimus treatment is
mainly due to translational regulation, because mRNA lev-
els of neither protein show a decrease with sirolimus treat-
ment. It is unlikely that the reduction of MMP-2 andMMP-
14 in sirolimus-treated rats ismainly due to TIMP inhibition
because the active form of TIMP-2 remained unchanged.
Increased TIMP-2 expression has been shown in Cy/+ rats
by in situ hybridization, but when TIMP-2 RNA expression
was analysed in total kidney by an RNase protection assay,
no pronounced effect was seen and the favourable effect
of batimastat on cyst growth was different from TIMP-2
expression [18]. In line with this result is our finding that
sirolimus treatment did not change TIMP-2 expression. In
8-week-old Cy/+ rats, an increased expression of TIMP-2
was found in proximal tubules [22]. We cannot exclude
that in the early disease stage, locally expressed TIMP-2 is
associated with cyst development. Although in our study
we cannot prove a direct effect of sirolimus on MMP-2 and
MMP-14 expression, it is plausible that part of the benefi-
cial effects of sirolimus might be caused by inhibition of
MMPs.
Renal fibrosis is a hallmark of cystic disorder in hu-
man ADPKD [27] and in Han:SPRD rats [28]. Fibrosis
increases with the progression of disease, indicating a link
between cystogenesis and fibrogenesis. It is therefore dif-
ficult to deduce the effect of sirolimus on reduced cyst
growth from improved MMP activities, and it can either
be a consequence of the specific action of sirolimus or the
reflection of the overall improvement of the severity of the
disease. A number of recent studies show that sirolimus
has prominent therapeutic effects on various renal dis-
eases where matrix production and fibrosis are enhanced.
In a model for experimental membranous nephropathy, a
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Fig. 6. TIMP-2 protein expression. (A) Western blot analyses and (B) densitometry revealed three forms of TIMP-2: the active form (TIMP-2 free
form), the dimer TIMP-2 and the complex TIMP-2/MMP-14 are depicted by three bands of 27 kD, 54 kD and 70 kD, respectively. Whereas the two
complexes appeared to be strongly increased in heterozygous (Cy/+) kidneys, the free form was not differentially expressed compared to the wild-type
(+/+). Sirolimus treatment decreased the TIMP-2 complexed forms in +/+ and Cy/+ rats, but did not affect the levels of TIMP-2 active form. Two
representative samples for each group are depicted. ∗P < 0.05 compared with the untreated wild-type (+/+) rats, n = 4 per group.
relatively low dose of sirolimus resulted in reduced
interstitial inflammation and fibrosis [29]. Treatment
with sirolimus blunted compensatory renal hypertrophy;
a similar effect has been observed in the rat model
for hydronephrosis [30]. Sirolimus also blocked tubular
epithelial-to-mesenchymal transition, a critical step in fi-
brogenesis. These results support the hypothesis that the
beneficial effect of sirolimus is not only mediated by its
antiproliferative effect but by multiple mechanisms.
In conclusion, MMP-2, MMP-14 and TIMP-2 are dys-
regulated in the Han:SPRD rat model of ADPKD. The ac-
tivation of MMP-2 and MMP-14 is markedly suppressed in
vivo by the treatment of Han:SPRD rats with sirolimus, and
this is correlated with less matrix and TBM alterations and
milder cystic disease.
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